Bio-Rad Laboratories (NYSE:BIO) jumped 0.01 points or 0.01% on strong buying and was last priced at $142.93 per share. The shares saw huge fund flow intraday; a massive $0.03 million made their way in through the upticks but an even bigger $0.34 million made their way out through downticks. As per the last observation, the net money flow stood at $(-0.31) million and the up/down ratio was found to be 0.08. The shares have seen a weekly value change of 1.43% .
The stock has recorded a 20-day Moving Average of 3.18% and the 50-Day Moving Average is 1.26%. The company shares have dropped 4.59% in the past 52 Weeks. On July 15, 2015 The shares registered one year high of $152.38 and one year low was seen on January 20, 2016 at $122.03. The 50-day moving average is $144.97 and the 200 day moving average is recorded at $136.98. S&P 500 has rallied 1.93% during the last 52-weeks.
Bio-Rad Laboratories (NYSE:BIO): The stock opened at $142.69 on Tuesday but the bulls could not build on the opening and the stock topped out at $143.62 for the day. The stock traded down to $141.03 during the day, due to lack of any buying support eventually closed down at $141.83 with a loss of -0.76% for the day. The stock had closed at $142.92 on the previous day. The total traded volume was 111,253 shares.
Currently the company Insiders own 28.38% of Bio-Rad Laboratories shares according to the proxy statements. Institutional Investors own 63.03% of Bio-Rad Laboratories shares. On the companys insider trading activities, Hall Shannon, officer (Executive Vice President) of Bio Rad Laboratories Inc, unloaded 1,572 shares at an average price of $145.3 on June 13, 2016. The total amount of the transaction was worth $228,412, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies products and systems used for the life science research, healthcare, analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials, and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Companys Life Science segment develops, manufactures and markets a range of over 5,000 reagents, apparatus and laboratory instruments. The Companys Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rads product brands include Droplet Digital and BioPlex. As of December 31, 2014, the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.